The Varicella-Zoster Virus Vaccines: Benefits and Risks
Varicella (chickenpox) and herpes zoster (shingles) are distinc clinical entities caused by Varicella-zoster virus (VZV). Varicella is a highly contagious exanthema that occurs most often in children. In normal children, systemic symptoms are usually mild and serious complications are rare. In adult...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book Section PeerReviewed |
| Language: | English English English |
| Published: |
Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI)
2018
|
| Subjects: | |
| Online Access: | http://repository.unair.ac.id/86924/1/The%20Varicella-Zoster%20Virus%20Vaccines_%20Benefit%20and%20Risks.pdf http://repository.unair.ac.id/86924/2/The%20Varicella%20Zoster_compressed.pdf http://repository.unair.ac.id/86924/3/The%20Varicella-Zoster.pdf http://repository.unair.ac.id/86924/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Universitas Airlangga |
| Language: | English English English |
| Summary: | Varicella (chickenpox) and herpes zoster (shingles) are distinc clinical entities caused by Varicella-zoster virus (VZV). Varicella is a highly contagious exanthema that occurs most often in children. In normal children, systemic symptoms are usually mild and serious complications are rare. In adult and immunologically compromised persons, varicella is more likely to be associated with life-threatening complications. Herpes zoster (HZ) is a viral disease characterized by a dermatologic and neurologic involvement caused by the reactivation of the latent varicella zoster virus (VZV) acquired during primary infection (varicella). HZ incidence increases with age and is related to waning specific cell-mediated immunity (CMI). Pain is an important clinical manifestation of herpes zoster, and the most common debilitating complication is chronic pain or post-herpetic neuralgia (PHN) characterized by chronic pain lasting at least 30 days, with impact on patients’ quality of life. Available treatments are quite unsatisfactory in reducing pain and length of the disease. The evaluation of the epidemiology, the debilitating complications of varicella and HZ, the sub-optimal available treatments and the costs related to the diagnosis and clinical/therapeutic management of varicella and HZ patients have been rationale for the search of an adequate preventive measure against these diseases. The use of varicella vaccine reduces the incidences, hospitalization, and complications of varicella. Zoster vaccine reduces the incidence of herpes zoster by one-half and the incidence of PHN by two-thirds. Clinical studies show a good level of efficacy and effectiveness, particularly against the burden of illness and PHN in all age classes. Herpes zoster vaccine is needed for older person to reduce the incidences, hospitalization, and complications of herpes zoster, especially PHN. |
|---|